Mesotheliomas Pleural
17
8
12
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.9%
1 terminated out of 17 trials
50.0%
-36.5% vs benchmark
6%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (17)
A Study of Sacituzumab Govitecan in People With Mesothelioma
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
The IMmunotherapy Pleural 5-ALA PDT
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
CAR T Cells in Mesothelin Expressing Cancers
dENdritic Cell Therapy Combined With SURgEry in Mesothelioma
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
Ga-68 FAPI PET Before Immunotherapy
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors